Rallybio Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rallybio Corp (RLYB) on September 9, 2026, reporting events occurring on September 8, 2026. The company is an emerging growth company incorporated in Delaware and trades on the NASDAQ Capital Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and employment status changes.
Material Changes
- Executive Employment Status: Jonathan Lieber, Chief Financial Officer (CFO) and Principal Financial Officer, will transition to part-time employment effective September 15, 2026.
- Compensation Adjustment: Following the transition, Mr. Lieber will receive a base salary of $420,000 and remain eligible for benefit plans. He will not be entitled to an annual bonus for 2026 or any subsequent year during his employment.
- Role Continuity: Despite the part-time status, Mr. Lieber retains the same duties and authority as CFO.
Outlook, Risks, and Contingencies
Pending Business Combination: Mr. Lieber's employment is contingent upon the closing of a pending business combination with Avenzo Therapeutics, Inc. pursuant to an Agreement and Plan of Merger dated May 31, 2026. His employment will terminate upon the closing of this transaction unless earlier terminated by either party.
Severance: Upon termination, Mr. Lieber is entitled to severance payments as defined in his original Employment Agreement (dated February 1, 2023) and the Second Amendment (dated June 1, 2026).
Investor Verification Checklist
- Verify the status and timeline of the pending merger with Avenzo Therapeutics, Inc.
- Review the full text of the Employment Side Letter (Exhibit 10.1) for additional terms.
- Confirm the specific severance amounts and conditions in the referenced Employment Agreement and Second Amendment.
- Monitor for any further announcements regarding the CFO's role or the merger closing date.